PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Neurotherapeutics. Author manuscript; available in PMC Apr 1, 2010.
Published in final edited form as:
PMCID: PMC2700027
NIHMSID: NIHMS108792
Alteration of Epileptogenesis Genes
Amy R. Brooks-Kayal, M.D.,1,2 Yogendra H. Raol, Ph.D.,1 and Shelley J. Russek, Ph.D.3
1Division of Neurology, Department of Pediatrics, University of Colorado Denver School of Medicine, Aurora, CO 80045
2The Children’s Hospital, Aurora, CO 80045
3Laboratory of Translational Epilepsy, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, 02118.
Amy R. Brooks-Kayal: brooks-kayal.amy/at/tchden.org; Yogendra H. Raol: yogendra.raol/at/ucdenver.edu; Shelley J. Russek: srussek/at/bu.edu
Retrospective studies suggest that precipitating events such as prolonged seizures, stroke or head trauma increase the risk of developing epilepsy later in life. The process of epilepsy development, known as epileptogenesis, is associated with changes in the expression of a myriad of genes. One of the major challenges to the epilepsy research community has been to determine which of these changes contributes to epileptogenesis, which may be compensatory, and which may be non-contributory. Establishing this for any given gene is essential if it is to be considered a therapeutic target for the prevention or treatment of epilepsy. Our laboratories have examined alterations in gene expression related to inhibitory neurotransmission that have been proposed as contributing factors in epileptogenesis. The GABAA receptor (GABAR) mediates most fast synaptic inhibition, and changes in GABAR subunit expression and function have been reported in adult animals beginning immediately after prolonged seizures (status epilepticus (SE)) and continue as animals become chronically epileptic. Prevention of GABAR subunit changes after SE using viral gene transfer inhibits development of epilepsy in an animal model, suggesting that these changes directly contribute to epileptogenesis. The mechanisms that regulate differential expression of GABAR subunits in hippocampus after SE have recently been identified, and include the CREB/ICER, JAK/STAT, BDNF and Egr3 signaling pathways. Targeting signaling pathways that alter the expression of genes involved in epileptogenesis may provide novel therapeutic approaches for preventing or inhibiting the development of epilepsy after a precipitating insult.
Keywords: GABA, receptor subunits, epilepsy, epileptogenesis, hippocampus, gene transfer, transcriptional regulation
It is clear from the results of research using various animal models and from human retrospective studies that an initial precipitating event such as status epilepticus (SE) can increase the risk of later epilepsy development (epileptogenesis). The process of epileptogenesis is likely to be complex and multifactorial. Determining whether changes in gene regulation that accompany the epileptic condition are consequential or causative of disease etiology is the major difficulty of research in this area. Many laboratories, including our own, have focused on the role of gene regulation in determining changes in γ-aminobutyric acid (GABA) receptor plasticity that occur during the latent period after brain insult and prior to the development of the epileptic state. GABA is the major inhibitory neurotransmitter in the mature brain, and various drugs that enhance GABAergic inhibition are commonly used as antiepileptic drugs. Also, drugs that block GABAergic inhibition can induce seizures in animals, further supporting the potential importance of alterations in GABAergic transmission in epileptogenesis.
Three types of GABA receptors, GABAA, GABAB and GABAC, are found in the mature central nervous system. GABAA and GABAC are ionotropic receptors, whereas, GABAB is a metabotropic receptor. Most fast synaptic inhibition in the mature brain is mediated by GABAA receptors (GABARs), whereas slow inhibition is mediated by GABAB receptors. GABARs are composed of multiple subunit subtypes (α1-6, β1-3, γ1-3, δ, ε, π, θ and ρ1-3) that form a pentameric anion-selective channel.1,2 The most common in vivo subunit composition is two α, two β and one γ subunit. There is remarkable receptor heterogeneity, with subtype combinations varying in different brain regions, cell types, and during different times in ontogeny.3,4,5,6 Different subunit subtypes confer distinct functional and pharmacological properties to the receptors.3
Prolonged seizures (status epilepticus or SE) result in alterations in the expression and membrane localization of several GABAR subunits (α1, α4, γ2, δ) in hippocampal dentate granule neurons.7-9 These alterations, which are associated with changes in phasic and tonic GABAR -mediated inhibition, and in GABAR modulation by benzodiazepines, neurosteroids, and zinc, begin soon after SE and continue as animals become epileptic.7-10 Several laboratories have documented changes in GABAR subunit composition in human temporal lobe epilepsy (TLE) and in animal models of TLE.7,9,11,12 In the pilocarpine model of SE in adult rodents, GABAR α1 subunit mRNA expression decreases, α4 subunit mRNA expression increases in dentate granule cells (DGCs) of the hippocampus, and animals uniformly go on to develop the recurrent spontaneous seizures that define epilepsy.7 The change in subunit expression correlates with a decreased sensitivity to zolpidem augmentation and increased sensitivity to zinc inhibition of GABAR responses.7 Similar functional and subunit expression changes have been observed in DGCs isolated from surgically resected hippocampus from patients with intractable TLE.12 The changes in GABAR subunit expression and function in DGCs of epileptic animals precede the development of epilepsy, suggesting that these changes contribute to the epileptogenesis process. In contrast, neonatal SE (postnatal day 10) in rats results in increased GABAR α1 subunit expression and does not lead to the subsequent development of epilepsy.13
These studies suggest that GABAR subunit alterations may be an important component of epileptogenesis. To more directly determine if GABAR changes are critical contributors to epilepsy development, we utilized gene transfer to prevent these GABAR subunit changes. To directly test the hypothesis that the expression of higher α1 subunit levels inhibits development of epilepsy after SE, an adeno-associated virus (AAV) gene transfer vector (AAV2)- serotype 5 was designed to express a bicistronic RNA that codes for both the GABAR α1 subunit as well as the reporter, enhanced yellow fluorescence protein (eYFP).14 Expression of this RNA was placed under control of the GABAR α4 subunit gene (GABRA4) core promoter region, because it was previously shown to be markedly activated in dentate gyrus (DG) following SE,15 thus following SE, activity of the α4 promoter is upregulated, resulting in enhanced α1 expression in DG. AAV-vectors containing either the α1/eYFP fused cDNA (AAV-α1) or the eYFP-reporter only (AAV-eYFP) was injected into DG of adult rats, and SE was induced two weeks later by intraperitoneal injection of pilocarpine (385 mg/kg).14 Rats injected with AAV-α1 showed 3-fold higher levels of α1 subunits in DG by 2 weeks after SE compared to the control groups. Rats were continuously video-EEG monitored to determine the latency for the development of spontaneous seizures. AAV-α1 injection resulted in a 3-fold increase in the mean time to the first spontaneous seizure following SE, and only 39% of AAV-α1 injected rats were observed to develop spontaneous seizures in the first 4 weeks after SE, as compared to 100% of rats receiving sham-injections. Because all groups of rats experienced similar SE after pilocarpine injection, these findings provide the first direct evidence that increasing the levels of a single GABAR subunit in DG can inhibit the development of spontaneous seizures after SE. Together, these data support a role for GABAR α-subunit changes in the process of epileptogenesis.
α1 subunit regulation
Although viral gene transfer is a promising therapeutic avenue to modify aberrant gene expression associated with epileptogenesis, producing the optimal level of expression over a prolonged period can be challenging. Another potential approach is to modify the mechanisms regulating gene expression. Recent work in our laboratories has established cAMP response element binding protein (CREB) and inducible cAMP early repressor (ICER) as critical mediators of GABAR α1 subunit mRNA decreases that occur after SE in the DG. The CREB is a stimulus-induced bZIP transcription factor that is activated by phosphorylation at its Ser 133 site. Phosphorylated CREB (pCREB) dimerizes and binds to cAMP response element (CRE) motifs on promoters that contain the consensus sequence TGACGTCA.16 Along with its chromatin regulator, the CREB binding protein (CBP), pCREB upregulates transcription of target genes. Transcriptional regulation through CREB has been implicated in mechanisms of cell survival, plasticity, and learning and memory paradigms.17 Target genes of pCREB include CREB family members, which consist of cAMP response element modulator (CREM), ICER and activating transcription factor (ATF). These para- and homologs of CREB also bind CRE elements to modulate the transcription of particular genes. The CREM gene produces many spliced isoforms that can act as transcriptional repressors or activators. One of these repressor forms is ICER, a group of 4 proteins made from an internal promoter in the CREM gene.18 ICER can act as a homodimer at the CRE site or heterodimerize with CREB to directly block CREB-induced transcription.
The human α1 promoter contains a functional CRE,19 making CREB and its family members potential regulators of α1 gene expression in epilepsy. Several studies using adult animal models of epilepsy suggest that seizures upregulate pCREB or CREM/ICER activity.20,21 Our laboratory has found sustained increases in both pCREB and ICER in the DG of the hippocampus, continuing 1-48 hours after pilocarpine induced SE.22 Using chromatin immunoprecipitation (ChIP) and DNA pulldown studies, increased pCREB and ICER binding at the CRE site of GABAR α1 subunit gene (GABRA1) were also observed after SE.22 Further, in transfected primary hippocampal neurons manipulating CREB and ICER levels showed that over-expression of CREB and ICER together decreases GABRA1 promoter/reporter activity and overexpression of ICER alone decreases the levels of endogenous α1 subunits at the cell surface.23 These findings suggest that CREB and ICER are important regulators of seizure-induced GABRA1 changes.
The excessive neuronal activity associated with SE stimulates many different signaling pathways that could result in enhanced phosphorylation of CREB and expression of ICER.24 Determining which of these pathways mediates the increase in ICER expression critical for decreased transcription of the GABAR α1 subunit is crucial to understanding how crosstalk between different signaling pathways can lead to specific changes in inhibitory neurotransmission. The focus of our studies was on Brain Derived Neurotrophic Factor (BDNF) as a potential regulator of ICER because BDNF expression increases markedly after SE,25-29 and because BDNF differentially regulates the abundance of both α1 and α4 subunits in cultured neurons.29 Results demonstrated that BDNF treatment of primary hippocampal neurons in culture produces similar changes in α subunit levels as observed after SE. 24 hours after BDNF treatment, α1 levels decrease 42% and α4 levels increase 120%.29
How does BDNF regulate α1 subunit levels? Surprisingly, it relies on activation of the Janus kinase (JAK)/ Signal Transducer and Activators of Transcription (STAT) pathway that in turn controls the synthesis of ICER, a repressor of GABRA1 transcription. The JAK-STAT pathway is activated by cytokines binding to their specific receptors, resulting in transphosphorylation of JAK kinases that then lead to phosphorylation of STAT proteins.30-34 Phosphorylation of STATs on tyrosine residues leads to STAT homo- or heterodimerization, translocation from the cytoplasm to the nucleus and binding to specific DNA elements (STAT-recognition sites) to regulate target gene expression.31,32,35 Such an element is found in the ICER promoter and we have shown that pSTAT3 association with this site is enhanced after SE in DG.22 Furthermore, siRNA knockdown of STAT3 inhibits BDNF-induced ICER, as does blockade of JAK/STAT signaling pathway with pyridone 6 (P6) in primary hippocampal cultures. Most importantly, P6 administration in vivo into dentate gyrus prior to SE blocks both ICER induction and decreased transcription of GABRA1.22 These findings suggest that the interplay of the CREB, JAK/STAT, and BDNF signaling pathways are critical for the decrease in α1 subunit levels that occurs in response to SE and that these pathways may provide novel therapeutic targets for epilepsy. In fact, several drugs that specifically inhibit the activity of JAK236,37 or block downstream STAT activation,38,39 have already been identified as potential agents in cancer chemotherapy and are in clinical trials. We are currently testing these agents in primary neuronal cultures to determine whether they may also provide alternative therapy for the future treatment of epilepsy. The relationship of cancer biology to neurobiology has not yet been described and it will be interesting to see how postmitotic cells of the nervous system use the molecules characteristic of proliferation to modulate their responses to injury.
α4 subunit regulation
GABARs that contain α4 subunits have unique pharmacologic properties such as insensitivity to benzodiazepines and increased sensitivity to zinc blockade.40 Receptors containing α4 subunits are most often found with the δ rather than γ subunit, in combination with αβ. These α4βδ GABARs are localized to extrasynaptic sites and contribute to tonic inhibition. A minor population of α4βγ2 GABARs are found within DG synapses where they are proposed to affect both the rise time and decay of synaptic currents.41 In addition to the decrease in α1 subunit expression, there is a marked increase in α4 subunit expression during epileptogenesis in TLE models that results in an increase in the abundance of α4γ2 containing receptors and a reduction in α1γ2 containing receptors.22 The change in receptor subtype from α1βγ2 to α4βγ2 may contribute to epileptogenesis, as α4 containing GABARs have been shown to desensitize rapidly, especially when assembled with β3 subunits.42 In addition, GABARs containing the α4 subunit are very sensitive to zinc blockade,40 as is seen in DGCs of epileptic brain.7 Our studies have shown that the alteration in α4 levels is transcriptionally mediated via an increase in the expression of the transcription factor early growth response factor 3 (Egr3).15 Egrs are a family of four proteins (Egr1, 2, 3 and 4) that share nearly identical zinc finger DNA binding domains and bind to a common Egr response element consensus sequence (ERE), GCG T/GGG GCG.43 Our laboratories have shown induction of Egr family transcription factors after SE, with increases in protein levels of Egr3 and enhanced binding of Egr3 to the GABAR α4 subunit gene (GABRA4) promoter in the DG of the hippocampus 24 hours after pilocarpine induced SE.15 Similar to its critical role in decreased expression of α1 containing GABARs, BDNF again is the endogenous signal that induces Egr3 synthesis and overexpression of α4 GABARs, however, now through different signaling pathways, protein kinase C (PKC) and mitogen activated protein kinase (MAPK),29 establishing its’ role as a multifunctional stimulator of altered inhibition in the hyperactivated nervous system (for summary see figure 1).
Figure 1
Figure 1
Differential expression of GABAA Receptor α subunits via BDNF-stimulated signal transduction pathways. Whether a GABAA receptor has an α1 or α4 subunit in its complex may have dramatic effects on brain inhibition. The results of (more ...)
The approach we describe of identifying changes in gene expression during epileptogenesis in critical brain regions and then examining the functional effect of preventing or augmenting these changes, has been applied to a number of genes as described below.
Galanin is a bioactive compound that co-exists with classical neurotransmitters and often inhibits their release. Galanin mediates its action via three types of G protein-linked receptors GaR1-3. It is abundant in several brain structures including hippocampus, where its action is predominantly inhibitory.44 In animal models of SE, there is an acute reduction in the levels of galanin in the hippocampus.44 Galanin injection before induction of SE shortenes the duration of SE,44 whereas, galanin knock out mice have an increased propensity to develop SE.45 Using a gene therapy approach, Haberman and colleagues46 showed that injection of AAV containing coding sequence for active galanin peptide into inferior collicular cortex increased the threshold for seizure generation to electrical stimulation. A recent study by Kanter-Schlifke and colleagues,47 showed that overexpression of galanin by injection of AAV containing a galanin gene in hippocampus decreased duration of afterdischarges and increased the latency to develop generalized seizures in the kindling model of epilepsy. A more direct approach to increase the activity of galanin is to use galanin receptor agonists that can cross the blood brain barrier. Recently galnon, a low-molecular weight (677 Dalton) galanin receptor ligand, has been shown to affect various physiological as well as pathological functions.48 Galnon has been shown to have anticonvulsant activity in the pentylenetetrazol induced seizure model, where galnon injection reduced the seizure score and increased the seizure latency.49
Neuropeptide Y (NPY) is a peptide that has been associated with a number of biologically important functions such as learning and memory. NPY mediates its action through six receptors (Y1-6) that belong to the G-protein coupled superfamily. A number of studies carried out in different animal models of epilepsy have observed that there is an increase in NPY expression in the mossy fiber pathway of the hippocampus suggesting a modulatory role of NPY in epileptic activity.50 Also, mice that lack NPY have a reduced threshold to develop seizures with pentylenetetrazol and develop spontaneous seizures.51 A recent study by Noe and colleagues52 showed that rats that were injected with AAV containing an NYP gene 14 weeks after SE induction halted the progression of seizure activity.
Adenosine is an inhibitory modulator that mediates it action through four G-protein coupled receptors A1, A2A, A2B and A3. Decreased adenosine levels53 and long-term reduction in A1 receptors54 have been observed in different animal models of epileptogenesis. Adenosine antagonists have been shown to reduce the threshold for seizure development.53 In the hippocampal kindling model of epilepsy, rats that were implanted with myoblast grafts that were engineered to release adenosine by inhibiting adenosine kinase, an enzyme that converts adenosine to adenosine 3’,5’-monophosphate, reduced seizure duration for 3 weeks after transplantation.55 Similarly, implantation of human mesenchymal stem cells transduced with lentivirus containing RNAi against adenosine kinase in the hippocampus of mice resulted in a 35% reduction in seizure duration following kainic acid injection compared to control mice that were implanted with scrambled control sequence.56 In another recent study, Wilz and colleagues57 showed that adenosine released from implants over a period of 14 days inhibited development of epilepsy in the kindling model. These studies provide a strong rationale for use of adenosine augmentation as a therapy for intractable epilepsy.
Glial Cell line-Derived Neurotrophic Factor (GDNF) is a member of GDNF family of trophic factors58 that has been shown to increase following seizures59 and intraventricular infusion of GDNF has been shown to suppress seizures in various animal models of epilepsy.60,61 A recent study by Kanter-Shilfke and colleagues62 showed that overexpression of GDNF using recombinant adeno-associated viral (rAAV) vector suppressed generalized seizure activity but could not prevent kindling epileptogenesis.
The full range of gene expression changes that are involved in epileptogenesis and the molecular mechanisms that underlie them are just beginning to be characterized. Studies in animal models suggest that modulation of the expression of a number of these genes via viral-mediated overexpression or manipulation of their upstream regulation may be useful therapeutic tools for the future treatment of epilepsy.
While the transcription factors discussed in this review likely compose only a part of the cascade of signaling events that are initiated by seizures, it is clear that the BDNF, JAK/STAT, CREB/ ICER and Egr3 signaling pathways play important roles. Recent work characterizing their functions in GABAR α1 and α4 subunit changes in the DG after SE provides an important lead for the future development of molecular therapies aimed at restoring the balance of excitation and inhibition in the nervous system. However, the upstream components of these pathways, and the exact means through which they confer vulnerability to epilepsy must be further elucidated. Further, as these pathways regulate a myriad of genes with diverse functions, modulation of any of these pathways may have a multitude of downstream effects, many of which may involve cell-and region-specific responses throughout the brain. Therefore, the final impact of pathway blockade on epileptogenesis may be difficult to predict. For example, although the enhanced GABAR α1-subunit expression in dentate gyrus that results from JAK/STAT pathway blockade and subsequent ICER inhibition would be expected to have an antiepileptic effect, mutant mice lacking ICER have accelerated kindling63 and develop more severe epilepsy following pilocarpine-induced SE.64 Consistent with this finding, ICER overexpressing mice show retardation of kindling development.63 Whether the effects of acute and transient blockade of ICER upregulation at the time of SE specifically in the hippocampal formation will have a similar effect on epileptogenesis as constitutive under- or over-expression of ICER globally in the brain remains to be determined. Finally, as several of these signaling pathways have been implicated in the regulation of learning, memory and cell survival, the effects of modulation of these pathways on these critical parameters will need to be closely monitored.
Promising data from animal models also supports the potential antiepileptic, and possibly antiepileptogenic, effects of altering the expression of several other neuromodulatory compounds including galanin, neuropeptide Y and adenosine. Just as with transcription factor modulation, however, there is still much work to be done to determine the methods for optimal treatment, such as when to initiate delivery and how long to treat. Equally important is how much modulation is necessary for treatment efficacy. Given the adaptive nature of the brain to overcome multiple insults, it would not be surprising if we find that small changes in gene expression using these approaches will have marked effects on restoring brain function. However, we are really at the starting gate because we know little about the long-term effects of such viral delivery on learning, memory, and cell survival. As all of the signal transduction pathways and neuromodulatory compounds discussed above have highly complex effects, impacting a plethora of receptors and their effector systems, we forsee the discovery of many more drug delivery targets making this area of inquiry particularly fertile for novel drug discovery in epilepsy.
Footnotes
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
1. Ticku MK, Mehta AK. An update on GABAA receptors. Brain Res Mol Brain Res. 1999;68(1–2):159–168. [PubMed]
2. Whiting PJ. The GABA-A receptor gene family: new targets for therapeutic intervention. Neurochem Int. 1999;34(5):387–390. [PubMed]
3. Vicini S. Pharmacologic significance of the structural heterogeneity of the GABAA receptor-chloride ion channel complex. Neuropsychopharmacology. 1991;14:9–15. [PubMed]
4. Laurie DJ, Wisden W, Seeburg PH. The distribution of thirteen GABAA receptor subunit mRNAs in the rat brain III Embryonic and postnatal development. J Neurosci. 1992;12:4151–4172. [PubMed]
5. Wisden W, Laurie DJ, Monyer H, Seeburg PH. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain I Telencephalon, diencephalon, mesencephalon. J Neurosci. 1992;12:1040–1062. [PubMed]
6. Macdonald RL, Olsen RW. GABAA receptor channels. Annu Rev Neurosci. 1994;17:569–702. [PubMed]
7. Brooks-Kayal AR, Shumate MD, Jin H, Rikhter TY, Coulter DA. Selective changes in single cell GABAA receptor subunit expression and function in temporal lobe epilepsy. Nat Med. 1998;4:1166–1172. [PubMed]
8. Peng Z, Huang CS, Stell BM, Mody I, Houser CR. Altered expression of the delta subunit of the GABAA receptor in a mouse model of temporal lobe epilepsy. J Neurosci. 2004;24:8629–8639. [PubMed]
9. Zhang N, Wei W, Mody I, Houser CR. Altered localization of GABAA receptor subunits on dentate granule cell dendrites influences tonic and phasic inhibition in a mouse model of epilepsy. J Neurosci. 2007;27(28):7520–7531. [PubMed]
10. Cohen AS, Lin DD, Quirk GL, Coulter DA. Dentate granule cell GABAA receptors in epileptic hippocampus: Enhanced synaptic efficacy and altered pharmacology. Eur J Neurosci. 2003;17:1607–1616. [PMC free article] [PubMed]
11. Houser CR, Esclapez M. Downregulation of the α5 subunit of the GABAA receptor in the pilocarpine model of temporal lobe epilepsy. Hippocampus. 2003;13(5):633–645. [PubMed]
12. Brooks-Kayal AR, Shumate MD, Jin H, et al. Human neuronal gamma-aminobutyric acid(A) receptors: coordinated subunit mRNA expression and functional correlates in individual dentate granule cells. J Neurosci. 1999;19(19):8312–8318. [PubMed]
13. Zhang G, Raol YH, Hsu FC, Coulter DA, Brooks-Kayal AR. Effects of status epilepticus on hippocampal GABAA receptors are age-dependent. Neuroscience. 2004;125(2):299–303. [PMC free article] [PubMed]
14. Raol YH, Lund IV, Bandyopadhyay S, et al. Enhancing GABAA receptor α1 subunit levels in hippocampal dentate gyrus inhibits epilepsy development in an animal model of temporal lobe epilepsy. J Neurosci. 2006;26:11342–11346. [PubMed]
15. Roberts DS, Raol YH, Bandyopadhyay S, et al. Egr3 stimulation of GABRA4 promoter activity as a mechanism for seizure-induced up-regulation of GABA(A) receptor alpha4 subunit expression. Proc Natl Acad Sci U S A. 2005;102:11894–11899. [PubMed]
16. Lonze BE, Ginty DD. Function and regulation of CREB family transcription factors in the nervous system. Neuron. 2002;35:605–623. [PubMed]
17. Jaworski JB, Mioduszewska A, Sanchez-Capelo I, et al. Inducible cAMP early repressor, an endogenous antagonist of cAMP responsive element-binding protein, evokes neuronal apoptosis in vitro. J Neurosci. 2003;23:4519–4526. [PubMed]
18. Molina CA, Foulkes NS, Lalli E, Sassone-Corsi P. Inducibility and negative autoregulation of CREM: an alternative promoter directs the expression of ICER, an early response repressor. Cell. 1993;75:875–886. [PubMed]
19. Steiger JL, Russek SJ. GABAA receptors: building the bridge between subunit mRNAs, their promoters, and cognate transcription factors. Pharmacol Ther. 2004;101:259–281. [PubMed]
20. Fitzgerald LR, Vaidya VA, Terwilliger RZ, Duman RS. Electroconvulsive seizure increases the expression of CREM (cyclic AMP response element modulator) and ICER (inducible cyclic AMP early repressor) in rat brain. J Neurochem. 1996;66:429–432. [PubMed]
21. Lee B, Dziema H, Lee KH, Choi YS, Obrietan K. CRE-mediated transcription and COX-2 expression in the pilocarpine model of status epilepticus. Neurobiol Dis. 2007;25:80–91. [PMC free article] [PubMed]
22. Lund IV, Hu Y, Raol YH, Russek SJ, Brooks-Kayal AR. BDNF selectively regulates GABAA receptor transcription by the activation of the JAK/STAT pathway. Science Signal. 2008;1(41):ra9. [PMC free article] [PubMed]
23. Hu Y, Lund IV, Gravielle MC, Farb DH, Brooks-Kayal AR, Russek SJ. Surface expression of GABAA receptors is transcriptionally controlled by the interplay of cAMP-response element-binding protein and its binding partner inducible cAMP early repressor. J Biol Chem. 2008;283(14):9328–9340. [PubMed]
24. McNamara JO, Huang YZ, Leonard AS. Molecular signals underlying epileptogenesis. Science STKE. 2006;356:re12. [PubMed]
25. Mudo G, Jiang XH, Timmusk T, Bindoni M, Belluardo N. Change in neurotrophins and their receptor mRNAs in the rat forebrain after status epilepticus induced by pilocarpine. Epilepsia. 1996;37:198–207. [PubMed]
26. Rudge JS, Mather PE, Pasnikowski EM, et al. Endogenous BDNF protein is increased in adult rat hippocampus after a kainic acid induced excitotoxic insult but exogenous BDNF is not neuroprotective. Exp Neurol. 1998;149:398–410. [PubMed]
27. Binder DK, Croll SD, Gall CM, Scharfman HE. BDNF and epilepsy: too much of a good thing? Trends Neurosci. 2001;24:47–53. [PubMed]
28. Altar CA, Laeng P, Jurata LW, et al. Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci. 2004;24:2667–2677. [PubMed]
29. Roberts DS, Hu Y, Lund IV, Brooks-Kayal AR, Russek SJ. Brain-derived neurotrophic factor (BDNF)-induced synthesis of early growth response factor 3 (Egr3) controls the levels of type A GABA receptor alpha 4 subunits in hippocampal neurons. J Biol Chem. 2006;281:29431–29435. [PubMed]
30. Darnell JE, Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415–1421. [PubMed]
31. Zhong Z, Wen Z, Darnell J. STAT3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994;264:95–98. [PubMed]
32. Zhong Z, Wen Z, Darnell J. STAT3 and STAT4: members of the family of signal transducers and activators of transcription. Proc Natl Acad Sci USA. 1994;91:4806–4810. [PubMed]
33. Schindler C, Darnell JE., Jr Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem. 1995;64:621–651. [PubMed]
34. Ihle JN. STATs: signal transducers and activators of transcription. Cell. 1996;84:331–334. [PubMed]
35. Aaronson DS, Horvath CM. A road map for those who don’t know JAK-STAT. Science. 2002;296:1653–1655. [PubMed]
36. Dowlati A, Nethery D, Kern JA. Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther. 2004;3(4):459–463. [PubMed]
37. Burdelya L, Catlett-Falcone R, Levitzki A, et al. Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone. Mol Cancer Ther. 2002;1(11):893–899. [PubMed]
38. Amit-Vazina M, Shishodia S, Harris D, et al. Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells. Br J Cancer. 2005;93(1):70–80. [PMC free article] [PubMed]
39. Faderl S, Ferrajoli A, Harris D, Van Q, Kantarjian HM, Estrov Z. Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells. Leuk Res. 2007;31(1):91–95. [PubMed]
40. White G, Gurley D. α subunits influence Zinc block of γ2 containing GABAA receptor currents. Neuroreport. 1995;6:461–464. [PubMed]
41. Jones-Davis DM, Macdonald RL. GABAA receptor function and pharmacology in epilepsy and status epilepticus. Curr Opin Pharmacol. 2003;3(1):12–18. [PubMed]
42. Lagrange AH, Botzolakis EJ, Macdonald RL. Enhanced macroscopic desensitization shapes the response of alpha4 subtype-containing GABAA receptors to synaptic and extrasynaptic GABA. J Physiol. 2007;578:655–676. [PubMed]
43. O’Donovan KJ, Tourtellotte WG, Millbrandt J, Baraban JM. The EGR family of transcription-regulatory factors: progress at the interface of molecular and systems neuroscience. Trends Neurosci. 1999;22:167–173. [PubMed]
44. Mazarati A, Liu H, Soomets U, et al. Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. J Neurosci. 1998;18:10070–10077. [PubMed]
45. Mazarati AM, Hohmann JG, Bacon A, et al. Modulation of hippocampal excitability and seizures by galanin. J Neurosci. 2000;20:6276–6281. [PubMed]
46. Haberman RP, Samulski RJ, McCown TJ. Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med. 2003;9(8):1076–1080. [PubMed]
47. Kanter-Schlifke I, Sørensen T, Ledri M, Kuteeva E, Hökfelt T, Kokaia M. Galanin gene transfer curtails generalized seizures in kindled rats without altering hippocampal synaptic plasticity. Neuroscience. 2007;150:984–992. [PubMed]
48. Sollenberg U, Bartfai T, Langel U. Galnon- a low-molecular weight ligand of the galanin receptors. Neuropeptides. 2005;39(3):161–163. [PubMed]
49. Saar K, Mazarati AM, Mahlapuu R, et al. Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci U S A. 2002;99(10):7136–7141. [PubMed]
50. Nadler VJ, Tu B, Timofeeva O, Jiao Y, Herzog H. Neuropeptide Y in the recurrent mossy fiber pathway. Peptide. 2007;28:357–364. [PMC free article] [PubMed]
51. Erickson JC, Clegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature. 1996;381:415–421. [PubMed]
52. No’e F, Pool AH, Nissinen J, et al. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain. 2008;131:1506–1515. [PubMed]
53. Young D, Dragunow M. Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms. Neuroscience. 1994;58(2):245–261. [PubMed]
54. Rebola N, Porciuncula LO, Lopes LV, Oliveira CR, Soares-da-silva P, Cunha RA. Long-term effect of convulsive behavior on the density of adenosine A1 and A2A receptors in the rat cerebral cortex. Epilepsia. 2005;46(S5):159–65. [PubMed]
55. Guttinger M, Padrun V, Pralong WF, Boison D. Seizure suppression and lack of adenosine A1 receptor desensitization after focal long-term delivery of adenosine by encapsulated myoblasts. Exp Neurol. 2005;193(1):53–64. [PubMed]
56. Ren G, Li T, Lan JQ, Wilz A, Simon RP, Boison D. Lentiviral RNAi-induced downregulation of adenosine kinase in human mesenchymal stem cell grafts: a novel perspective for seizure control. Exp Neurol. 2007;208(1):26–37. [PMC free article] [PubMed]
57. Wilz A, Pritchard EM, Li T, Lan JQ, Kaplan DL, Boison D. Silk polymer-based adenosine release: therapeutic potential for epilepsy. Biomaterials. 2008;29(26):3609–3616. [PMC free article] [PubMed]
58. Saavedra A, Baltazar G, Duarte EP. Driving GDNF expression: The green and the red traffic lights. Prog Neurobiol. 2008;86(3):186–215. [PubMed]
59. Mikuni M, Babb TL, Chakravarty DN, Christi W. Time course of transient expression of GDNF protein in rat granule cells of the bilateral dentate gyri after unilateral intrahippocampal kainic acid injection. Neurosci Lett. 1999;262(3):215–218. [PubMed]
60. Martin D, Miller G, Rosendahl M, Russell DA. Potent inhibitory effects of glial derived neurotrophic factor against kainic acid mediated seizures in the rat. Brain Res. 1995;683:172–178. [PubMed]
61. Li S, Xu B, Martin D, Racine RJ, Fahnestock M. Glial cell line-derived neurotrophic factor modulates kindling and activation-induced sprouting in hippocampus of adult rats. Exp Neurol. 2002;178:49–58. [PubMed]
62. Kanter-Schlifke I, Georgievska B, KiriK D, Kokaia M. Seizure suppression by GDNF gene therapy in animal models of epilepsy. Molecular Therapy. 2007;15(6):1106–113. [PubMed]
63. Kojima N, Borlikova G, Sakamoto T, et al. Inducible cAMP early repressor acts as a negative regulator for kindling epileptogenesis and long-term fear memory. J Neurosci. 2008;28(25):6459–6472. [PubMed]
64. Porter BE, Lund IV, Varodayan FP, Wallace RW, Blendy JA. The role of transcription factors cyclic-AMP responsive element modulator (CREM) and inducible cyclic-AMP early repressor (ICER) in epileptogenesis. Neuroscience. 2008;152(3):829–836. [PMC free article] [PubMed]